AP2006003486A0 - Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors. - Google Patents

Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors.

Info

Publication number
AP2006003486A0
AP2006003486A0 AP2006003486A AP2006003486A AP2006003486A0 AP 2006003486 A0 AP2006003486 A0 AP 2006003486A0 AP 2006003486 A AP2006003486 A AP 2006003486A AP 2006003486 A AP2006003486 A AP 2006003486A AP 2006003486 A0 AP2006003486 A0 AP 2006003486A0
Authority
AP
ARIPO
Prior art keywords
inhibitors
glycogen synthase
synthase kinase
triazolopyrimidine derivatives
triazolopyrimidine
Prior art date
Application number
AP2006003486A
Other languages
English (en)
Inventor
Peter Jacobs Johann Buijnsters
Marc Willems
Werner Constant Joha Embrechts
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of AP2006003486A0 publication Critical patent/AP2006003486A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AP2006003486A 2003-07-16 2004-07-12 Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors. AP2006003486A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP0350310 2003-07-16
PCT/EP2004/051455 WO2005012307A1 (fr) 2003-07-16 2004-07-12 Derives de triazolopyrimidine en tant qu'inhibiteurs de glycogene synthase kinase 3

Publications (1)

Publication Number Publication Date
AP2006003486A0 true AP2006003486A0 (en) 2006-02-28

Family

ID=34112425

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2006003486A AP2006003486A0 (en) 2003-07-16 2004-07-12 Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors.

Country Status (26)

Country Link
US (2) US7560458B2 (fr)
EP (1) EP1658292B1 (fr)
JP (1) JP2009514782A (fr)
KR (1) KR20060120393A (fr)
CN (1) CN100404536C (fr)
AP (1) AP2006003486A0 (fr)
AR (1) AR045698A1 (fr)
AT (1) ATE370142T1 (fr)
AU (1) AU2004260738B2 (fr)
BR (1) BRPI0412596A (fr)
CA (1) CA2531333A1 (fr)
DE (1) DE602004008303T2 (fr)
DK (1) DK1658292T3 (fr)
EA (1) EA010109B1 (fr)
ES (1) ES2290754T3 (fr)
IL (1) IL173139A (fr)
JO (1) JO2460B1 (fr)
MX (1) MXPA06000540A (fr)
NO (1) NO20060678L (fr)
NZ (1) NZ545058A (fr)
PA (1) PA8607001A1 (fr)
PL (1) PL1658292T3 (fr)
PT (1) PT1658292E (fr)
TW (1) TW200524935A (fr)
WO (1) WO2005012307A1 (fr)
ZA (1) ZA200600385B (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
MXPA05001096A (es) 2002-07-29 2005-11-23 Rigel Pharmaceuticals Inc Metodos para tratamiento o prevencion de enfermedades autoinmunes con compuestos de 2,4-diamino-pirimidina.
CN100404536C (zh) * 2003-07-16 2008-07-23 詹森药业有限公司 作为糖原合酶激酶3抑制剂的***并嘧啶衍生物
KR20120062863A (ko) 2003-07-30 2012-06-14 리겔 파마슈티칼스, 인크. 자가면역 질환의 치료 또는 예방에 사용하기 위한 2,4-피리미딘디아민 화합물
CA2533320A1 (fr) * 2003-08-15 2006-02-24 Novartis Ag 2, 4-pyrimidine diamines utiles dans le cadre du traitement de maladies neoplasiques, de troubles inflammatoires et de troubles du systeme immunitaire
NZ546611A (en) * 2003-09-18 2010-02-26 Conforma Therapeutics Corp Novel heterocyclic compounds as HSP90-inhibitors
CA2580787A1 (fr) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Derives heterocycliques et utilisation de ceux-ci comme agents therapeutiques
CN101083992A (zh) 2004-09-20 2007-12-05 泽农医药公司 抑制人硬脂酰CoA去饱和酶的哒嗪衍生物
AR051092A1 (es) 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa
TW200626138A (en) 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
EP2269610A3 (fr) 2004-09-20 2011-03-09 Xenon Pharmaceuticals Inc. Dérivés hétérocycliques et leur utilisation en tant qu'inhibiteurs de la stearoyl-coa desaturase
AU2005286648A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
MX2007003327A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos, y su uso como mediadores de estearoil-coa desaturasa.
DE602005023333D1 (de) 2004-10-15 2010-10-14 Takeda Pharmaceutical Kinaseinhibitoren
MX2007005159A (es) * 2004-10-29 2007-06-26 Tibotec Pharm Ltd Derivados de pirimidina biciclicos inhibidores del vih.
WO2006076442A2 (fr) * 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. Derives de triazolopyrimidine
CA2618646A1 (fr) 2005-06-03 2007-11-15 Xenon Pharmaceuticals Inc. Derives aminothiazole utilises en tant qu'inhibiteurs de la stearoyle-coa desaturase humaine
WO2006133426A2 (fr) 2005-06-08 2006-12-14 Rigel Pharmaceuticals, Inc. Compositions et procedes d'inhibition de la voie jak
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US7678363B2 (en) 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
EP2258359A3 (fr) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenèse par modulation des récepteurs muscariniques avec sabcomeline
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
EP1940389A2 (fr) 2005-10-21 2008-07-09 Braincells, Inc. Modulation de la neurogenese par inhibition de la pde
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US8962643B2 (en) 2006-02-24 2015-02-24 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2021000A2 (fr) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenèse par modulation de l'angiotensine
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
GEP20135728B (en) 2006-10-09 2013-01-25 Takeda Pharmaceuticals Co Kinase inhibitors
TWI444379B (zh) 2007-06-29 2014-07-11 Sunesis Pharmaceuticals Inc 有用於作為Ｒａｆ激酶抑制劑之化合物
CA2694284A1 (fr) * 2007-06-29 2009-01-08 Jennifer Cossrow Composes heterocycliques utiles en tant qu'inhibiteurs de la kinase raf
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
JP5607241B2 (ja) 2010-05-21 2014-10-15 ケミリア・エービー 新規ピリミジン誘導体
WO2012127032A1 (fr) 2011-03-24 2012-09-27 Chemilia Ab Nouveaux dérivés de pyrimidine
CN104066734B (zh) * 2012-01-28 2017-03-29 默克专利股份公司 ***并[4,5‑d]嘧啶衍生物
CA2866450C (fr) 2012-03-07 2020-02-18 Merck Patent Gmbh Derives de triazolopyrazine
US9617266B2 (en) 2013-03-05 2017-04-11 Merck Patent Gmbh Imidazopyrimidine derivatives
WO2014135244A1 (fr) * 2013-03-05 2014-09-12 Merck Patent Gmbh Dérivés de triazolo[4,5-d]pyrimidine pour le traitement de maladies telles que le cancer
CA2911259A1 (fr) 2013-05-06 2014-11-13 Merck Patent Gmbh Macrocycles utilises en tant qu'inhibiteurs de kinases
EP3226861A2 (fr) * 2014-12-05 2017-10-11 Centre National de la Recherche Scientifique (CNRS) Composés pour le traitement de la mucoviscidose
WO2017035528A1 (fr) 2015-08-27 2017-03-02 Nantneuro, Llc Triazolopyridines et triazolopyrimidines qui abaissent la p-tau induite par le stress
US11203576B2 (en) * 2016-03-11 2021-12-21 H. Lee Moffitt Cancer Center And Research Institute, Inc. Aurora kinase and Janus kinase inhibitors for prevention of graft versus host disease
AU2020218366A1 (en) 2019-02-08 2021-09-16 Frequency Therapeutics, Inc. Valproic acid compounds and Wnt agonists for treating ear disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5962594A (ja) * 1982-09-30 1984-04-10 Ss Pharmaceut Co Ltd ３，５―ジ置換―トリアゾロピリミジン誘導体
US20020040031A1 (en) * 2000-07-07 2002-04-04 Glasky Michelle S. Methods for prevention of accumulation of amyloid beta peptide in the central nervous system
US6737085B2 (en) * 2000-11-01 2004-05-18 Tokiwa Phytochemical Co., Ltd. Apocynum venetum extract for use as antidepressant
WO2002050073A1 (fr) * 2000-12-19 2002-06-27 Smithkline Beecham P.L.C. Pyrazolo[3,4-c]pyridine en tant qu'inhibiteurs de gsk-3
CN100404536C (zh) * 2003-07-16 2008-07-23 詹森药业有限公司 作为糖原合酶激酶3抑制剂的***并嘧啶衍生物

Also Published As

Publication number Publication date
PT1658292E (pt) 2007-10-25
PA8607001A1 (es) 2005-05-10
IL173139A (en) 2010-04-29
EP1658292B1 (fr) 2007-08-15
DK1658292T3 (da) 2007-11-12
AU2004260738A1 (en) 2005-02-10
EA200600258A1 (ru) 2006-06-30
EP1658292A1 (fr) 2006-05-24
ZA200600385B (en) 2007-05-30
DE602004008303T2 (de) 2008-05-08
CN1823068A (zh) 2006-08-23
US7560458B2 (en) 2009-07-14
KR20060120393A (ko) 2006-11-27
EA010109B1 (ru) 2008-06-30
NZ545058A (en) 2008-05-30
AR045698A1 (es) 2005-11-09
CA2531333A1 (fr) 2005-02-10
DE602004008303D1 (de) 2007-09-27
TW200524935A (en) 2005-08-01
WO2005012307A1 (fr) 2005-02-10
ATE370142T1 (de) 2007-09-15
ES2290754T3 (es) 2008-02-16
US20090036471A1 (en) 2009-02-05
NO20060678L (no) 2006-02-10
AU2004260738B2 (en) 2009-07-16
CN100404536C (zh) 2008-07-23
MXPA06000540A (es) 2006-03-30
JO2460B1 (en) 2009-01-20
BRPI0412596A (pt) 2006-09-19
IL173139A0 (en) 2006-06-11
US20060205721A1 (en) 2006-09-14
PL1658292T3 (pl) 2008-01-31
JP2009514782A (ja) 2009-04-09

Similar Documents

Publication Publication Date Title
AP2006003486A0 (en) Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors.
HRP20180578T1 (hr) Pirolo[2,3-b]piridin-4-il-amini i pirolo[2m3-b]pirimidin-4-il-amini kao inhibitori janus kinaze
AP2005003353A0 (en) Diazepinoindole derivatives as kinase inhibitors.
HRP20181912T1 (hr) Derivati pirolo[2,3-d]pirimidina kao inhibitori janus kinaze
IL172132A0 (en) Thienopyridone derivatives as kinase inhibitors
AP2005003452A0 (en) Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors.
SI2395004T1 (sl) Derivati piro (2,3-b) piridina kot inhibitorji proteinske kinaze
IL173381A0 (en) 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
IL173380A0 (en) Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors
IL165515A0 (en) Bisindolyl-maleimid derivatives as kinase inhibitors
HK1086012A1 (en) 8-substitued-6,7,8,9-tetrahydropyrimidoÄ1,2-aÜ pyrimidin-4-one derivatives
EP1590333A4 (fr) Inhibiteur de glycogene synthase kinase 3beta, composition et procede de preparation associe
HK1093503A1 (en) Pyrido 2, 1-a-isoquinoline derivatives as ddp-IV inhibitors
HK1088893A1 (en) Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimidoÄ1,2-aÜ pyrimidin-4-one derivatives
IL173200A0 (en) Piperidyl-quinazoline derivatives as tyrosine kinase inhibitors
AP2214A (en) Pyrrolo [3,4-c] pyrazole derivatives active as kinase inhibitors.
IL172375A0 (en) Chinazoline derivatives as aurora kinase inhibitors
HK1071758A1 (en) Pyrazolopyridines as cyclin dependent kinase inhibitors
ZA200802690B (en) Thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors
EP1638557A4 (fr) Inhibiteurs de la glycogene synthase kinase-3
IL178688A0 (en) THIENO [3,2-b] PYRIDINE-6-CARBONITRILES AS PROTEIN KINASE INHIBITORS
TH123620B (th) เพอโรโล[2,3-b]เพอริดิน-4-อิล-เอมีน (pyrrolo[2,3-b]pyridin-4-yl)aminies) และ เพอโรโล[2,3-b]เพอริดิน-4-อิล-เอมีน เป็นตัวยับยั้งเจนัส โคเนส (Janus Kinase Inhibitor)
SI1483265T1 (sl) Drivati purina kot inhibitoriji kinaze